Sains Malaysiana 40(5)(2011): 475–479
Survivin Expression in Uterine Cervical
Exfoliative Cells as Diagnostic Test of Cervical Malignancy Process
(Pernyataan
Survivin dalam Sel-sel Eksfoliatif Pangkal Rahim sebagai Ujian Diagnostik
daripada Proses-proses Malignan Pangkal Rahim)
Zulham*
Department of
Histology, Faculty of Medicine, University of Sumatera Utara
Jl. Dr. Mansur No.
5 Medan 20155 Sumatera Utara, Indonesia
Ahmad Aulia Jusuf
Department of
Histology, Faculty of Medicine, University of Indonesia
Jl. Salemba Raya
No. 6 Jakarta 10430, Indonesia
Junita Indarti
Dr. Cipto
Mangunkusumo Hospital, Department of Obstetrics and Gynecology
Faculty of Medicine,
University of Indonesia
Jl. P. Diponegoro
No. 71 Jakarta 1043, Indonesia
Lisnawati
Dr. Cipto
Mangunkusumo Hospital, Department of Anatomic Pathology
Faculty of Medicine,
University of Indonesia
Jl. P. Diponegoro
No. 71 Jakarta 10430, Indonesia
Received: 13 August
2009 / Accepted: 11 October 2010
ABSTRACT
Papanicolaou test is a
diagnostic test for uterine cervical cancer screening and routinely examined.
It has limitations. A better technique is needed to identify true cervical
malignancy process. Molecular cancer marker detection may have high the
sensitivity and specificity in detecting cancer. Survivin, a marker candidate,
is upregulated in many malignancy processes. Ninety women have joined in this
cross sectional study by consecutive sampling. Survivin expression was examined
by indirect immunoperoxidase method. It was predominantly found in metaplastic
cells. Correlation between survivin expression and Papanicolaou test results
was calculated by Fischer’s-exact test. Using Papanicolaou test result as an
indicator for the presence of uterine cervical abnormalities, the performance
indicators were calculated. Fischer’s-exact test showed that survivin
expression was not significantly useful as cervical cancer molecular marker.
Survivin expression of the uterine cervical exfoliative cells cannot be used as
a diagnostic test for uterine cervical malignancy process.
Keywords: Diagnostic test;
indirect immunoperoxidase; Papanicolaou test; survivin; uterine cervical cancer
ABSTRAK
Ujian Papanicolau adalah
sebuah ujian diagnostik bagi pemeriksaan barah pangkal rahim (kanser serviks)
dan dilakukan secara rutin. Ujian ini mempunyai beberapa had. Suatu teknik yang
lebih baik diperlukan bagi mengenal pasti proses malignansi serviks yang
sebenarnya. Survivin, satu calon penanda kanser, meningkat kadarnya dalam
banyak proses malignansi. Sembilan puluh wanita telah menyertai kajian keratan
lintang ini melalui pensampelan berturutan. Pernyataan survivin diperiksa
dengan menggunakan kaedah imunoperoksidas tidak langsung. Korelasi antara
ekspresi survivin dengan keputusan ujian Pap dikira dengan menggunakan ujian
Fischer’s-exact. Seterusnya, dengan menggunakan keputusan yang diperoleh
daripada ujian Papanicolau sebagai penunjuk adanya keganjilan serviks, penunjuk
prestasi daripada immunositokimia daripada survivin boleh dikira. Ujian
Fischer’s-exact menunjukkan bahawa ekspresi survivin tidak berguna secara penuh
makna sebagai penanda kanser serviks secara molekular. Pernyataan survivin
daripada sel-sel eksfoliatif serviks tidak boleh digunakan sebagai ujian
diagnostik bagi proses malignan serviks.
Kata kunci: Imunoperoksidas
tidak langsung; kanser pangkal rahim; survivin; ujian diagnostik; ujian
Papanicolaou
REFERENCES
Ashanuma,
K., Tsuji, N., Endoh, T., Yagihashi, A. &
Watanabe, N. 2004. Survivin enhances Fas ligand expression via up-regulation of
specifity protein-1 mediated gene transcription in colon cancer cells. The
Journal of Immunology 172: 3922-3929.
Branca,
M., Giorgi, C., Santini, D., Bonito, L.D., Ciotti, M., Costa, S., Benedetto,
A., Casolati, E.A., Favalli, C., Paba, P., Di Bonito, P., Mariani, L.,
Syrjänen, S., Bonifacio, D., Accardi, L., Zanconati, F. & Syrjänen, K.
2005. Survivin as a marker of cervical intraepithelial neoplasia and high-risk
human papilloma virus and a predictor of virus clearance and prognosis in
cervical cancer. American Journal of Clinical Pathology 124: 113-121.
Cannistra,
S.A. & Niloff, J.M. 1996. Cancer of the uterine cervix. The New England
Journal of Medicine 334: 1030-1038.
Carlson,
M.W. 2006. Gene expression profiling and modeling of cervical cancer, Ph D
Dissertation. Austin: Texas Univ.
Chen, Y., Miller, C.,
Mosher, R., Zhao, X., Deeds, J., Morissey, M., Bryant, B., Yang, D., Meyer, R.,
Cronin, F., Gostout, B.S., Smith-McCune, K. & Schlegel, R. 2003.
Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer
Research 63: 1927-1935.
Frost,
M., Jarboe, E.A., Orlicky, D., Gianani, R., Thompson, L.C., Enomoto, T. &
Shroyer, K.R. 2002. Immunohistochemical localization of survivin in benign
cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. American
Journal of Clinical Pathology 117: 738-744.
Geisler,
J.P., Geisler, H.E., Miller, G.A., Wiemann, M.C., Zhou, Z., Miller, J. &
Crabtree, W. 2002. Serum and molecular biological markers in cervical carcinoma
and cervical carcinoma in situ. Continuing Medical Education Journal of
Gynecologic Oncology 6(1): 81-85.
Li,
F. 2003. Survivin study: What is the next wave? Journal of Cellular
Physiology 197: 8-29.
Li,
F. 2005. Role of survivin and its splice variants in tumorigenesis. British
Journal of Cancer 92: 212-216.
Lu,
B., Mu, Y., Cao, C., Zeng, F., Schneider, S., Tan, J., Price, J., Chen,
J., Freeman, M. & Hallahan, D.E. 2004. Survivin as a therapeutic target for
radiation sensitization in lung cancer. Cancer Research 64: 2840-2845.
Maddox,
P., Sasieni, P., Szarewski, A., Anderson, M. & Hanby, A. 1999. Differential
expression of keratins 10, 17, and 19 in normal cervical epithelium, cervical
intraepithelial neoplasia, and cervical carcinoma. Journal of Clinical
Pathology 52: 41-46.
Nakanishi,
K., Kawai, T., Kumaki, F., Hiroi, S., Mukai, M. & Ikeda, E. 2003. Survivin
expression in atypical adenomatous hyperplasia of the lung. American Journal
of Clinical Pathology 120: 712-719.
Pusponegoro,
H.D., Wirya, I.G.N.W., Pudjiadi, A.H., Bisanto, J. & Zulkarnain, S.Z. 2006. Uji diagnostik in Dasar-dasar Metodologi Penelitian Klinis. 2nd Ed.
Sastroasmoro S, Ismael S. Eds. Jakarta: Sagung Seto.
Rodel,
F., Hoffmann, J., Distel, D., Herrmann, M., Noisternig, T., Papadopoulos, T.,
Sauer, R. & Rödel, C. 2005. Survivin as a radioresistance factor, and
prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer
Research 65: 4881-4887.
Salz,
W., Eisenberm, D., Plescia, J., Garlick, D.S., Weiss, R.M., Wu, X-R.
et al. 2005. A survivin gene signature predicts aggresive tumor behavior. Cancer
Research 65: 3531-3534.
Tjindarbumi,
D. & Mangunkusumo, R. 2002. Cancer in Indonesia, present and future. Japanese
Journal of Clinical Oncology 32 suppl I: S17-21.
Vischioni,
B., van der Valk, P., Span, S.W., Kruyt, F.A.E., Rodriguez, J.A. &
Giaccone, G. 2004. Nuclear localization of survivin is a positive prognostic
factor for survival in advanced non-small-cell lung cancer. Annals of
Oncology 15: 1654-1660.
WHO.
2002. Cervical Cancer Screening in Developing Countries: Report of a WHO
Consultation. Geneva: WHO.
Williams,
G.H., Romanowski, P., Morris, L., Madine, M., Mills, A.D., Stoeber, K., Marr,
J., Laskey, R.A. & Coleman, N. 1998. Improved cervical smears assessment
using antibodies against proteins that regulate DNA replication. Proceedings
of the National Academy of Sciences of the United States of America 95:
14932-14937.
*Corresponding author;
e-mail: dr_zulham@yahoo.com
|